CClinicalTrials.gg
CompletedNCT00476502Updated Apr 5, 2012

Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r

An observational study in HIV Infections, sponsored by The HIV Netherlands Australia Thailand Research Collaboration. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-05.

Sponsored by The HIV Netherlands Australia Thailand Research Collaboration · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

Study of genetic polymorphisms of CYP #A and MDR-1 genes in Thai HIV-1 infected patients on saquinavir/ritonavir.

Read the detailed description

Genetic polymorphisms will be investigated by polymerase-chain reaction (PCR) and drug levels of saquinavir will be determined by high phase liquid chromatography with UV-detected (HPLC).

02

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • genetic polymorphism
  • CYP 3A
  • MDR-1
  • Thai
  • HIV
  • Treatment Experienced
03

In context

HIV Infections

4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.

This study's enrollment of 250 is above the median of 200 across 713 observational studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

The HIV Netherlands Australia Thailand Research Collaboration is the lead sponsor of 59 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients on stable SQV based HAART therapy

Inclusion criteria

  • HIV-infected persons who have been enrolled in the Staccato study
  • On low-dose ritonavir boosted saquinavir at the time blood samples are collected

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the nature and extent of the study and the procedures required
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1

    patients involved in structured interruption therapy

    Genetic: identify genetic polymorphism in Thai HIV infected

Interventions

  • Geneticidentify genetic polymorphism in Thai HIV infected

    Gene sequencing of Cyp450 metabolic pathway

06

Study locations

1 site
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
    Bangkok, 10330, Thailand
07

References and documents

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00476502
Lead sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
May 22, 2007
Start date
Feb 2006
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Apr 5, 2012

Study contacts

Kiat Ruxrungtham, MD
principal investigator · The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion